The mortality rate from influenza in the United States is by far highest among those aged 65 years and older. During the 2023-2024 flu season, the mortality rate from influenza for this age group was around 32.1 per 100,000 population. The burden of influenza The impact of influenza in the U.S. varies from season to season, but in the 2023-2024 flu season, there were an estimated 40 million cases. These cases resulted in around 470,000 hospitalizations. Although most people recover from influenza without requiring medical treatment, the disease can be deadly for young children, the elderly, and those with weakened immune systems or chronic illnesses. During the 2023-2024 flu season, around 28,000 people in the U.S. lost their lives due to influenza. Impact of vaccinations The most effective way to prevent influenza is to receive an annual vaccination at the beginning of flu season. Flu vaccines are safe and can greatly reduce the burden of the disease. During the 2022-2023 flu season, vaccinations prevented around 2,479 deaths among those aged 65 years and older. Although flu vaccines are usually cheap and easily accessible, every year a large share of the population in the U.S. still does not get vaccinated. For example, during the 2022-2023 flu season, only about 35 percent of those aged 18 to 49 years received a flu vaccination.

The burden of influenza in the United States can vary from year to year depending on which viruses are circulating, how many people receive an influenza vaccination, and how effective the vaccination is in that particular year. During the 2023-2024 flu season, around 28,000 people lost their lives to the disease. Although most people recover from influenza without needing medical care, the disease can be deadly among young children, the elderly, and those with weakened immune systems or chronic illnesses. Deaths due to influenza Even though most people recover from influenza without medical care, influenza and pneumonia can be deadly, especially for older people and those with certain preexisting conditions. Influenza is a common cause of pneumonia and although most cases of influenza do not develop into pneumonia, those that do are often more severe and more deadly. Deaths due to influenza are most common among the elderly, with a mortality rate of around 32 per 100,000 population during the 2023-2024 flu season. In comparison, the mortality rate for those aged 50 to 64 years was 9.1 per 100,000 population. Flu vaccinations The most effective way to prevent influenza is to receive an annual influenza vaccination. These vaccines have proven to be safe and are usually cheap and easily accessible. Nevertheless, every year a large share of the population in the United States still fails to get vaccinated against influenza. For example, in the 2022-2023 flu season, only 35 percent of those aged 18 to 49 years received a flu vaccination. Unsurprisingly, children and the elderly are the most likely to get vaccinated. It is estimated that during the 2022-2023 flu season, vaccinations prevented over 929 thousand influenza cases among children aged 6 months to 4 years.

In 2022, the highest death rate from influenza and pneumonia in Canada per 100,000 population was reported among those aged 90 years and older, with around *** deaths. Individuals between 85 and 89 years followed, with a mortality rate from influenza and pneumonia of almost *** deaths per 100,000 people. This statistic displays the death rate from influenza and pneumonia per 100,000 population in Canada during 2022, by age.

ObjectivesThe aim of this study is to describe, visualize, and compare the trends and epidemiological features of the mortality rates of 10 notifiable respiratory infectious diseases in China from 2004 to 2020.SettingData were obtained from the database of the National Infectious Disease Surveillance System (NIDSS) and reports released by the National and local Health Commissions from 2004 to 2020. Spearman correlations and Joinpoint regression models were used to quantify the temporal trends of RIDs by calculating annual percentage changes (APCs) in the rates of mortality.ResultsThe overall mortality rate of RIDs was stable across China from 2004 to 2020 (R = −0.38, P = 0.13), with an APC per year of −2.2% (95% CI: −4.6 to 0.3; P = 0.1000). However, the overall mortality rate of 10 RIDs in 2020 decreased by 31.80% (P = 0.006) compared to the previous 5 years before the COVID-19 pandemic. The highest mortality occurred in northwestern, western, and northern China. Tuberculosis was the leading cause of RID mortality, and mortality from tuberculosis was relatively stable throughout the 17 years (R = −0.36, P = 0.16), with an APC of −1.9% (95% CI −4.1 to 0.4, P = 0.1000). Seasonal influenza was the only disease for which mortality significantly increased (R = 0.73, P = 0.00089), with an APC of 29.70% (95% CI 16.60–44.40%; P = 0.0000). The highest yearly case fatality ratios (CFR) belong to avian influenza A H5N1 [687.5 per 1,000 (33/48)] and epidemic cerebrospinal meningitis [90.5748 per 1,000 (1,010/11,151)]. The age-specific CFR of 10 RIDs was highest among people over 85 years old [13.6551 per 1,000 (2,353/172,316)] and was lowest among children younger than 10 years, particularly in 5-year-old children [0.0552 per 1,000 (58/1,051,178)].ConclusionsThe mortality rates of 10 RIDs were relatively stable from 2004 to 2020 with significant differences among Chinese provinces and age groups. There was an increased mortality trend for seasonal influenza and concerted efforts are needed to reduce the mortality rate of seasonal influenza in the future.

In 2021, there were **** death cases caused by the influenza virus in China. The death rate of the virus amounted to approximately ****** out of ten million people. Influenza, commonly known as "flu", is a highly contagious respiratory disease caused by influenza A or B viruses and can be prevented by vaccines. It should be noted that the Chinese health authorities calculate death cases for infectious diseases differently, counting only patients who died directly from the infectious disease.

Background: As of October 2020, COVID-19 has caused 1,000,000 deaths worldwide. However, large-scale studies of COVID-19 mortality and new-onset comorbidity compared to individuals tested negative for COVID-19 and individuals tested for influenza A/B are lacking. We investigated COVID-19 30-day mortality and new-onset comorbidity compared to individuals with negative COVID-19 test results and individuals tested for influenza A/B.Methods and findings: This population-based cohort study utilized electronic health records covering roughly half (n = 2,647,229) of Denmark's population, with nationwide linkage of microbiology test results and death records. All individuals ≥18 years tested for COVID-19 and individuals tested for influenza A/B were followed from 11/2017 to 06/2020. Main outcome was 30-day mortality after a test for either COVID-19 or influenza. Secondary outcomes were major comorbidity diagnoses 30-days after the test for either COVID-19 or influenza A/B. In total, 224,639 individuals were tested for COVID-19. To enhance comparability, we stratified the population for in- and outpatient status at the time of testing. Among inpatients positive for COVID-19, 356 of 1,657 (21%) died within 30 days, which was a 3.0 to 3.1-fold increased 30-day mortality rate, when compared to influenza and COVID-19-negative inpatients (all p < 0.001). For outpatients, 128 of 6,263 (2%) COVID-19-positive patients died within 30 days, which was a 5.5 to 6.9-fold increased mortality rate compared to individuals tested negative for COVID-19 or individuals tested positive or negative for influenza, respectively (all p < 0.001). Compared to hospitalized patients with influenza A/B, new-onset ischemic stroke, diabetes and nephropathy occurred more frequently in inpatients with COVID-19 (all p < 0.05).Conclusions: In this population-based study comparing COVID-19 positive with COVID-19 negative individuals and individuals tested for influenza, COVID-19 was associated with increased rates of major systemic and vascular comorbidity and substantially higher mortality. Results should be interpreted with caution because of differences in test strategies for COVID-19 and influenza, use of aggregated data, the limited 30-day follow-up and the possibility for changing mortality rates as the pandemic unfolds. However, the true COVID-19 mortality may even be higher than the stated 3.0 to 5.5-fold increase, owing to more extensive testing for COVID-19.

Abbreviations: ICU, intensive care unit.aRates were calculated using 2009 statewide age-specific population projections published by the State of California Department of Finance (URL: http://www.dof.ca.gov/research/demographic/data/race-ethnic/2000-50/).bExcludes non-hospitalized fatalities; the case-fatality ratio is calculated using the following formula: (number of fatal ICU cases from age group/total number of ICU cases within that age group)*100.

Following variables were used for confounding adjustment. All variables are measured at the time of hospital admission.

In 2023, the number of deaths from influenza in Japan decreased to 1383 cases, which marked an increase compared to just ** cases in the previous year. The death rate from influenza amounted to *** death cases per 100,000 inhabitants in 2023.

BackgroundThe disease burden associated with influenza in developing tropical and subtropical countries is poorly understood owing to the lack of a comprehensive disease surveillance system and information-exchange mechanisms. The impact of influenza on outpatient visits, hospital admissions, and deaths has not been fully demonstrated to date in south China.MethodsA time series Poisson generalized additive model was used to quantitatively assess influenza-like illness (ILI) and influenza disease burden by using influenza surveillance data in Zhuhai City from 2007 to 2009, combined with the outpatient, inpatient, and respiratory disease mortality data of the same period.ResultsThe influenza activity in Zhuhai City demonstrated a typical subtropical seasonal pattern; however, each influenza virus subtype showed a specific transmission variation. The weekly ILI case number and virus isolation rate had a very close positive correlation (r = 0.774, P < 0.0001). The impact of ILI and influenza on weekly outpatient visits was statistically significant (P < 0.05). We determined that 10.7% of outpatient visits were associated with ILI and 1.88% were associated with influenza. ILI also had a significant influence on the hospitalization rates (P < 0.05), but mainly in populations <25 years of age. No statistically significant effect of influenza on hospital admissions was found (P > 0.05). The impact of ILI on chronic obstructive pulmonary disease (COPD) was most significant (P < 0.05), with 33.1% of COPD-related deaths being attributable to ILI. The impact of influenza on the mortality rate requires further evaluation.ConclusionsILI is a feasible indicator of influenza activity. Both ILI and influenza have a large impact on outpatient visits. Although ILI affects the number of hospital admissions and deaths, we found no consistent influence of influenza, which requires further assessment.

3.67 (per 100,000 inhabitants) in 2018.

NNDSS - TABLE 1R. Hepatitis C, perinatal infection to Influenza-associated pediatric mortality - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notes: • These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance. Footnotes: *Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). § Please refer to the CDC WONDER publication for weekly updates to the footnote for this condition. U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

3.84 (per 100,000 inhabitants) in 2018.

Following the outbreak of the H1N1 influenza pandemic of 1918, which came to be known as the Spanish Flu, the number of deaths due to influenza and pneumonia soared. Pneumonia was caused either by the influenza or by a bacterial superinfection that took hold due to the patient's weakened state as a result of the influenza, for this reason, influenza deaths and pneumonia deaths were recorded together as one. Pennsylvania had the highest mortality rate due to the pandemic, where there were over 880 fatalities per 100,000 people; meaning that approximately 0.9 percent of the state's population died from the Spanish Flu pandemic in 1918.

When compared with the 1915 mortality rates, many states, such as California and Pennsylvania, saw their mortality rate due to influenza and pneumonia increase five-fold by 1818, which was the worst year of the pandemic. While the mortality rate decreased significantly in the year 1919, there was no US state where it fell to it's pre-pandemic level, and the 1919 mortality rate was still double the pre-pandemic rate in some states such as California, South Carolina and Washington.

Background # Seasonal influenza virus is a common cause of acute lower respiratory infection (ALRI) in young children. In 2008, we estimated that 20 million influenza-virus-associated ALRI and 1 million influenza-virus-associated severe ALRI occurred in children under 5 years globally. Despite this substantial burden, only a few low-income and middle-income countries have adopted routine influenza vaccination policies for children and, where present, these have achieved only low or unknown levels of vaccine uptake. Moreover, the influenza burden might have changed due to the emergence and circulation of influenza A/H1N1pdm09. We aimed to incorporate new data to update estimates of the global number of cases, hospital admissions, and mortality from influenza-virus-associated respiratory infections in children under 5 years in 2018. # Methods # We estimated the regional and global burden of influenza-associated respiratory infections in children under 5 years from a systematic review of 100 studies published between Jan 1, 1995, and Dec 31, 2018, and a further 57 high-quality unpublished studies. We adapted the Newcastle-Ottawa Scale to assess the risk of bias. We estimated incidence and hospitalisation rates of influenza-virus-associated respiratory infections by severity, case ascertainment, region, and age. We estimated in-hospital deaths from influenza virus ALRI by combining hospital admissions and in-hospital case-fatality ratios of influenza virus ALRI. We estimated the upper bound of influenza virus-associated ALRI deaths based on the number of in-hospital deaths, US paediatric influenza-associated death data, and population-based childhood all-cause pneumonia mortality data in six sites in low-income and lower-middle-income countries. # Findings # In 2018, among children under 5 years globally, there were an estimated 109*5 million influenza virus episodes (uncertainty range [UR] 63*1-190*6), 10*1 million influenza-virus-associated ALRI cases (6*8-15*1); 870 000 influenza-virus-associated ALRI hospital admissions (543 000-1 415 000), 15 300 in-hospital deaths (5800-43 800), and up to 34 800 (13 200-97 200) overall influenza-virus-associated ALRI deaths. Influenza virus accounted for 7% of ALRI cases, 5% of ALRI hospital admissions, and 4% of ALRI deaths in children under 5 years. About 23% of the hospital admissions and 36% of the in-hospital deaths were in infants under 6 months. About 82% of the in-hospital deaths occurred in low-income and lower-middle-income countries. # Interpretation # A large proportion of the influenza-associated burden occurs among young infants and in low-income and lower middle-income countries. Our findings provide new and important evidence for maternal and paediatric influenza immunisation, and should inform future immunisation policy particularly in low-income and middle-income countries.

Highly pathogenic avian influenza virus (HPAIV) has caused extensive mortalities in wild birds, with a disproportionate impact on raptors since 2021. The population-level impact of HPAIV can be informed by telemetry studies that track large samples of initially healthy, wild birds. We leveraged movement data from 71 rough-legged hawks (Buteo lagopus) across all major North American migratory bird flyways concurrent with the 2022–2023 HPAIV outbreak and identified a total of 29 mortalities, of which 11 were confirmed, and an additional ~9 were estimated to have been caused by HPAIV. We estimated a 28% HPAIV cause-specific mortality rate among rough-legged hawks during a single year concurrent with the HPAIV outbreak in North America. Additionally, the overall annual mortality rate during the HPAIV outbreak (47%) was significantly higher than baseline annual mortality rates (3–17%), suggesting that HPAIV-caused deaths were additive above baseline mortality levels. HPAIV mortalities were concentrated within the Central and Atlantic flyways during pre-breeding migration and peaked in April 2022 when large-scale HPAIV mortalities were reported in other wild birds throughout North America. HPAIV exposure was most likely caused by scavenging or preying on infected waterfowl, as rough-legged hawks are known to opportunistically scavenge during the nonbreeding season. We utilized movement data to identify a continental-scale HPAIV cause-specific mortality event in rough-legged hawks that has the potential to exacerbate ongoing population declines. Our study highlights the usefulness of monitoring movement data to pinpoint sources of mortality that can help better understand the drivers of population change, even if studies are focused on other research questions.

BackgroundInfluenza and respiratory syncytial virus (RSV) associated mortality has not been well-established in tropical Africa.MethodsWe used the negative binomial regression method and the rate-difference method (i.e. deaths during low and high influenza/RSV activity months), to estimate excess mortality attributable to influenza and RSV using verbal autopsy data collected through a health and demographic surveillance system in Western Kenya, 2007–2013. Excess mortality rates were calculated for a) all-cause mortality, b) respiratory deaths (including pneumonia), c) HIV-related deaths, and d) pulmonary tuberculosis (TB) related deaths.ResultsUsing the negative binomial regression method, the mean annual all-cause excess mortality rate associated with influenza and RSV was 14.1 (95% confidence interval [CI] 0.0–93.3) and 17.1 (95% CI 0.0–111.5) per 100,000 person-years (PY) respectively; and 10.5 (95% CI 0.0–28.5) and 7.3 (95% CI 0.0–27.3) per 100,000 PY for respiratory deaths, respectively. Highest mortality rates associated with influenza were among ≥50 years, particularly among persons with TB (41.6[95% CI 0.0–122.7]); and with RSV were among <5 years. Using the rate-difference method, the excess mortality rate for influenza and RSV was 44.8 (95% CI 36.8–54.4) and 19.7 (95% CI 14.7–26.5) per 100,000 PY, respectively, for all-cause deaths; and 9.6 (95% CI 6.3–14.7) and 6.6 (95% CI 3.9–11.0) per 100,000 PY, respectively, for respiratory deaths.ConclusionsOur study shows a substantial excess mortality associated with influenza and RSV in Western Kenya, especially among children <5 years and older persons with TB, supporting recommendations for influenza vaccination and efforts to develop RSV vaccines.

Clinical and demographic characteristics of hospitalized children with confirmed influenza A and B in Buenos Aires, Argentina, 2000–2015 (n = 394).